Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Up 29.6% in February

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 26,700 shares, a growth of 29.6% from the January 31st total of 20,600 shares. Based on an average daily volume of 42,200 shares, the short-interest ratio is presently 0.6 days. Currently, 0.4% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a report on Wednesday, December 11th.

Lisata Therapeutics Stock Up 3.3 %

Shares of LSTA traded up $0.08 during trading hours on Thursday, hitting $2.45. 1,355 shares of the company were exchanged, compared to its average volume of 52,786. Lisata Therapeutics has a fifty-two week low of $2.05 and a fifty-two week high of $4.20. The company has a market cap of $20.56 million, a price-to-earnings ratio of -0.98 and a beta of 1.14. The firm’s fifty day moving average is $2.91 and its 200 day moving average is $2.90.

Lisata Therapeutics (NASDAQ:LSTA) last released its earnings results on Thursday, February 27th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.21. The firm had revenue of $1.00 million during the quarter. Analysts anticipate that Lisata Therapeutics will post -2.66 EPS for the current year.

Institutional Investors Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 45.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,226 shares of the company’s stock after buying an additional 7,886 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.30% of Lisata Therapeutics worth $75,000 at the end of the most recent reporting period. 8.94% of the stock is currently owned by institutional investors and hedge funds.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.